Cartazolate
Cartazolate is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive [allosteric modulator] at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and Adenosine [A2 receptor (disambiguation)|A2 subtypes] and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R. Squibb and Sons in the 1970s.